13F Holdings
中文EN

TOVX Theriva Biologics, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 894158 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY66.7%
TTM EPS YoY-44.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-99.8%
ROA-28.0%
ROIC (approx.)-956.5%
Asset turnover—

Leverage & solvency

Liabilities / assets65.9%
Debt / equity0.00x
Current ratio1.21x
Interest coverage-138.77x

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio8.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$8.60M$12.03M$14.31M$11.72M$7.80M
SG&A expense$15.45M$7.40M$7.12M$9.86M$6.47M
Operating income-$24.05M-$26.35M-$21.43M-$21.58M-$14.27M
Interest expense$61,000$6,000———
Pretax income-$23.74M-$25.65M-$19.99M-$21.11M-$14.27M
Income tax—$0-$1.64M-$1.43M$0
Net income-$23.74M-$25.65M-$18.35M-$19.68M-$14.27M
EBITDA-$23.94M-$26.21M-$21.30M-$21.50M-$14.19M
EPS (basic)-2.08-19.03-28.48-1.31-1.90
EPS (diluted)-2.08-19.03-28.48-1.31-1.90
Weighted avg. shares (diluted)12.14M1.35M644,28215.33M12.19M
Balance sheet
Cash & equivalents$13.06M$11.71M$23.28M$41.88M$67.33M
Current assets$17.47M$16.28M$27.40M$45.52M$68.86M
PP&E, net$222,000$270,000$422,000$345,000$101,000
Goodwill—$0$5.70M$5.53M$0
Intangibles$19.62M$17.36M$19.75M$19.15M—
Total assets$38.24M$35.35M$55.22M$71.86M$70.36M
Current liabilities$10.01M$7.58M$6.74M$7.06M$3.55M
Short-term debt——$63,000$57,000—
Long-term debt$1.67M$92,000$162,000$221,000—
Total debt$1.67M$92,000$225,000$278,000—
Total liabilities$22.86M$16.29M$15.52M$17.30M$4.96M
Shareholders' equity$15.38M$19.07M$36.96M$51.83M$65.41M
Net debt-$11.38M-$11.61M-$23.05M-$41.61M—
Shares outstanding35.69M2.78M686,21915.12M13.20M
Cash flow statement
Operating cash flow-$16.67M-$16.94M-$19.00M-$19.08M-$12.89M
Capital expenditure$35,000$1,000$202,000$116,000$14,000
Free cash flow-$16.70M-$16.94M-$19.20M-$19.20M-$12.90M
Investing cash flow-$35,000-$1,000-$202,000-$4.40M-$14,000
Financing cash flow$18.19M$5.50M$625,000-$1.93M$74.00M
Depreciation & amortization$108,000$137,000$135,000$85,000$87,000
Stock-based compensation$654,000$671,000$552,000$475,000$416,000

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.